Bogle Investment Management’s Puma Biotechnology PBYI Stock Holding History

Bogle Investment Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-33,664	Closed	-$340K	–	231
2020 Q3	$340K	Buy	33,664 +15,964	+90%	+$163K	0.1%	194
2020 Q2	$185K	Buy	+17,700	New	+$183K	0.03%	293
2020 Q1	–	Sell	-162,141	Closed	-$1.42M	–	335
2019 Q4	$1.42M	Sell	162,141 -154,333	-49%	-$1.28M	0.13%	154
2019 Q3	$3.41M	Buy	316,474 +53,529	+20%	+$578K	0.29%	104
2019 Q2	$3.34M	Buy	+262,945	New	+$6.06M	0.26%	115
2019 Q1	–	Sell	-195,589	Closed	-$3.98M	–	361
2018 Q4	$3.98M	Buy	+195,589	New	+$5.87M	0.31%	111
2017 Q3	–	Sell	-8,586	Closed	-$750K	–	337
2017 Q2	$750K	Buy	+8,586	New	+$480K	0.05%	239
2016 Q3	–	Sell	-395,750	Closed	-$11.8M	–	422
2016 Q2	$11.8M	Buy	395,750 +234,672	+146%	+$7.34M	0.82%	38
2016 Q1	$4.73M	Buy	+161,078	New	+$7.28M	0.32%	105
2013 Q3	–	Sell	-123,473	Closed	-$5.48M	–	338
2013 Q2	$5.48M	Buy	+123,473	New	+$4.35M	0.67%	56

Other funds holding PBYI

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bogle Investment Management's PBYI Position: Q4 2020 in Review

Bogle Investment Management sold out of Puma Biotechnology (PBYI) in Q4 2020, closing a stake of 33,664 shares — an estimated $340K sold.

Bogle Investment Management first reported a position in PBYI in Q2 2013 and held it in 10 quarters. The position peaked at $11.8M in Q2 2016. 123 funds tracked by Wall St. Rank hold PBYI as of Q4 2020.

Bogle Investment Management reported no remaining Puma Biotechnology position as of Q4 2020 after selling out during the quarter.
Bogle Investment Management sold 33,664 Puma Biotechnology shares in Q4 2020, an estimated $340K.
Bogle Investment Management first reported a position in Puma Biotechnology in Q2 2013 and held it in 10 quarters.
Bogle Investment Management's Puma Biotechnology position peaked at $11.8M in Q2 2016.
123 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2020.

Based on Bogle Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.